HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief

This article was originally published in The Rose Sheet

Executive Summary

FDA Raises Eyebrow At RapidLash Claims

You may also be interested in...



In Brief

Revlon is closing facilities and reducing headcount to “drive operating efficiencies,” the firm says. More news in brief.

House Hearing Probes FDA’s Cosmetics Role

Stakeholders from industry, government and FDA discussed ideas for changing the agency’s oversight of cosmetics at a House subcommittee meeting March 27. The need for a national regulatory system, mandatory recalls, company and ingredient registration and adverse event reporting were debated.

Avon Rebounds On Fragrance And Cosmetics, Strength In Latin America

After a disappointing 2010, things are looking up for Avon Products. For its fiscal 2011 first quarter, the firm booked revenue of $2.6 billion, up 7% over the same period last year, with a strong contribution from fragrance and color cosmetics, while profit tripled to reach $144 million.

Related Content

UsernamePublicRestriction

Register

RS017537

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel